Comments
Shares of Dr Reddy’s Laboratories surged over six per cent after the company said it has received the Establishment Inspection Report (EIR) from the USFDA for its Hyderabad facility.
The company had yesterday said it has received an EIR from USFDA on December 11 as closure of audit for its formulations manufacturing plant - 3 at Bachupally, Hyderabad. Dr Reddy’s was issued a form 483 with 11 observations.
Following the development, shares of the company opened on a bullish note at Rs 2,306, then surged to a high of Rs 2,328, registering a 6.13 per cent jump over its previous closing price. Similar movement was seen on the NSE, where the stock opened at Rs 2,324.50 and touched a high of Rs 2,326.40, up 6.08 per cent over its last close.
On April 28, the company had said:“These observations are mostly procedural in nature, reflecting the need to improve people’s capabilities and strengthen documentation and laboratory systems. We will address them comprehensively within the stipulated time.''
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.